Skip to main content

Animations

MJFF Publications

4761 - 4770 of 6456 Results
Title
Year
  • Year
  • 2024
  • 2020
  • 2019
  • 2016
  • 2020
  • 2025
  • 2025
  • 2019
  • 2016
  • 2021
  • Summary Details
    OPEN
    Title: Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-024-00789-w
    Citation Count: 34
  • Summary Details
    OPEN
    Title: Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2020.4725
    Citation Count: 143
  • Summary Details
    OPEN
    Title: Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-181518
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Parkinson’S Disease is Ready for Precision Medicine
    Journal Name: Personalized Medicine
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.2217/pme-2016-0052
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Genetic Testing for Parkinson Disease
    Journal Name: Neurology Clinical Practice
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/cpj.0000000000000831
    Citation Count: 39
  • Summary Details
    OPEN
    Title: Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.adr2511
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Reply to: “Refutation of the αSyn ‐ SAA ‐Based Staging for Parkinson's Progression (Neuronal α‐Synuclein Disease‐Integrated Staging System [NSD ‐ ISS] )”
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.30272
    Citation Count: 1
  • Summary Details
    OPEN
    Title: The Parkinson's disease e‐diary: Developing a clinical and research tool for the digital age
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27673
    Citation Count: 61
  • Summary Details
    OPEN
    Title: Using Qualitative Methods to Understand Physical Activity and Weight Management Among Bangladeshis in New York City, 2013
    Journal Name: Preventing Chronic Disease
    Publisher: Centers for Disease Control and Prevention - Preventing Chronic Disease
    Publication Date:
    Open Access(OA) Status: OPEN
    License: public-domain
    DOI - Digital Object Identifier: 10.5888/pcd13.160077
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-021-26066-5
    Citation Count: 220
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.